1. Volume 74, Issue 3, Pages 324-333 (September 2018)
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis 
Con Kelleher, Zalmai Hakimi, Richard Zur, Emad Siddiqui, Khaled Maman, Samuel Aballéa, Jameel Nazir, Chris Chapple 
European Urology 
Volume 74, Issue 3, Pages (September 2018)
DOI: /j.eururo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
PRISMA flow diagram showing study selection process and rationale for exclusions. EMBASE=Excerpta Medica database; NMA=network meta-analysis; PRISMA=Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Efficacy of mirabegron 50mg versus antimuscarinics: (A) micturition frequency (mean change from baseline in number of episodes/24h); (B) UUI (mean change from baseline in number of episodes/24h); (C) dry rate (number of patients with zero incontinence episodes or 100% reduction in incontinence episodes) a; and (D) 50% reduction in incontinence episodes (number of patients) b. CrI=credible intervals; ER=extended release; Mir=mirabegron; Sol=solifenacin; UUI=urgency urinary incontinence. a No UUI episodes or 100% reduction in UUI episodes were used as the definition for dry rate in seven studies, including the following comparators: placebo, fesoterodine, trospium, and tolterodine ER. b For 50% reduction in incontinence episodes, all data for fesoterodine (one placebo-controlled trial) are based on reduction of UUI only.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. Fig. 3
Tolerability of mirabegron 50mg versus antimuscarinics (all number of patients): (A) dry mouth, (B) constipation, (C) blurred vision, and (D) hypertension. CrI=credible intervals; ER=extended release; IR=immediate release; Mir=mirabegron; Sol=solifenacin.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

5. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020)
Copyright © 2018 European Association of Urology Terms and Conditions

6. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020)
Copyright © 2018 European Association of Urology Terms and Conditions

7. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020)
Copyright © 2018 European Association of Urology Terms and Conditions

8. European Urology 2018 74, 324-333DOI: (10.1016/j.eururo.2018.03.020)
Copyright © 2018 European Association of Urology Terms and Conditions